🧬 Aging Wiki

Nuclear cGAS restricts L1 retrotransposition by promoting TRIM41-mediated ORF2p ubiquitination and degradation

10 min read

Nuclear cGAS restricts L1 retrotransposition by promoting TRIM41-mediated ORF2p ubiquitination and degradation

Zhen Z, Chen Y, Wang H, Tang H, Zhang H, Liu H, Jiang Y, Mao Z · Nature Communications · 2023 · DOI: 10.1038/s41467-023-43001-y · PMID: 38086852 · PMC: PMC10716122

Senior author: Mao Z (same lab as chen-2025-nmr-cgas-hr-repair). Gold OA; full text at PMC10716122. Citation count: 34 (DOI lookup, 2026-05-13); FWCI: 6.59 (99th percentile citation impact). Local PDF downloaded during seeding.

TL;DR

Nuclear cgas serves as a genome-stability guardian against LINE-1 (L1) retrotransposition. Upon DNA damage, CHK2 phosphorylates cGAS at S120 and S305, strengthening its association with the E3 ubiquitin ligase trim41. trim41 then polyubiquitinates L1-encoded ORF2p (the reverse transcriptase/endonuclease), targeting it for proteasomal degradation. Loss of cGAS increased L1 retrotransposition 2.2–2.5-fold in human cells. The same pathway is active in senescent cells and is disrupted by 7 of 37 cancer-associated cGAS mutations. This is the conceptual prequel to chen-2025-nmr-cgas-hr-repair: it establishes the nuclear-cGAS / TRIM41 / ubiquitin axis that Chen 2025 later shows to operate on cGAS itself.

Background

LINE-1 (L1) retrotransposons comprise roughly 17% of the human genome. Normally silenced by DNA methylation and heterochromatin, L1 elements are progressively reactivated in aging and senescent cells, contributing to genomic instability through insertional mutagenesis and — crucially — to inflammaging through the generation of cytosolic L1 cDNA that activates cGAS-STING signaling 1. ORF2p is the L1-encoded reverse transcriptase and endonuclease essential for the retrotransposition “copy-paste” mechanism; it had lacked a characterized posttranslational regulatory pathway prior to Zhen et al. 2023.

cgas was previously known chiefly for two functions: (1) cytosolic DNA sensing that activates the cgas-sting pathway producing cGAMP → STING → IRF3 → type I IFN (the canonical inflammaging arm); and (2) nuclear HR suppression, wherein chromatin-bound cGAS obstructs repair-complex assembly at DNA double-strand breaks (Liu et al. 2018 — liu-2018-nuclear-cgas-hr-suppression if extant; otherwise 2). Zhen 2023 adds a third nuclear function: direct restriction of ORF2p protein levels through the TRIM41 ubiquitin-proteasome axis.

trim41 is a RING-type E3 ubiquitin ligase whose aging-context role was established primarily by this paper and by Chen 2025. Its coiled-coil domain mediates interaction with ORF2p; its RING domain catalyzes K48-linked polyubiquitination for proteasomal targeting.

Key findings

All quantitative data below are sourced from the PMC10716122 full text, pulled via WebFetch 3.

1. cGAS is required for L1 restriction in human cells

  • cGAS overexpression reduced L1 retrotransposition in HeLa cells in a dose-dependent manner 3.
  • cGAS knockout in HeLa cells increased retrotransposition efficiency by 2.2- and 2.5-fold (n=6 independent experiments) 3.
  • Genomic L1 copy number was significantly elevated in cGAS-deficient HeLa cells and in Cgas knockout mice (kidney and brain tissues; n=9 measurements from three independent mice per group; quantified by qPCR targeting genomic ORF2 DNA) 3. needs-human-replication

2. cGAS selectively targets ORF2p, not ORF1p

  • cGAS overexpression markedly reduced ORF2p protein levels with no effect on ORF1p levels 3.
  • ORF2p degradation was proteasome-dependent: the proteasome inhibitor MG132 blocked cGAS-mediated ORF2p reduction 3.
  • cGAS promoted K48-linked polyubiquitination of ORF2p — the canonical targeting signal for the 26S proteasome 3.

3. TRIM41 is the E3 ligase that bridges cGAS to ORF2p

  • Mass spectrometry of cGAS immunoprecipitates identified five candidate E3 ligases; only TRIM41 overexpression phenocopied the ORF2p reduction seen with cGAS 3.
  • TRIM41 knockout abolished cGAS-mediated suppression of L1 retrotransposition 3.
  • The EN domain of ORF2p and the coiled-coil domain of TRIM41 were the critical interaction surfaces 3.
  • The interaction model: cGAS binds ORF2p and scaffolds TRIM41 recruitment → TRIM41 polyubiquitinates ORF2p → proteasomal degradation → reduced retrotransposition 3.

4. DNA damage potentiates the restriction pathway via CHK2-mediated cGAS phosphorylation

  • Upon DNA damage, CHK2 phosphorylates cGAS at S120 and S305 (both within RXXS/RXXT phosphorylation consensus motifs) 3.
  • Phosphorylation strengthens the cGAS–TRIM41 interaction without altering the cGAS–ORF2p interaction 3.
  • S120A single mutant and S305A single mutant each partially abrogated the cGAS suppressive effect; the S120A/S305A double mutant reduced the inhibitory effect further than either single mutant alone 3.
  • CHK2 inhibition disrupted the damage-induced enhancement of cGAS-TRIM41 association 3.
  • Phosphorylation was detected specifically in the nuclear fraction, consistent with nuclear rather than cytosolic cGAS executing this function 3.

5. The pathway is active in senescent cells

  • Stress-induced premature senescent (SIPS) HeLa cells (induced by etoposide, 10 µg/mL, 20-min treatment on Day 4 post-transfection; FACS analysis Day 10) showed elevated CHK2 phosphorylation and increased cGAS S120 and S305 phosphorylation 3.
  • cGAS knockout attenuated L1 retrotransposition repression in SIPS HeLa cells (n=3 independent experiments) 3.
  • Nuclear localization of phosphorylated cGAS in senescent cells was also confirmed in X-ray-irradiated IMR90-hTERT and HCA2-hTERT fibroblasts (15 Gy; cells lysed on Day 9); these lines were used specifically for the subcellular fractionation validation of nuclear pS120/pS305-cGAS, not for the retrotransposition assay 3.

6. Cancer-associated cGAS mutations disrupt the restriction pathway

  • Of 37 cancer-associated cGAS mutants analyzed, 7 abolished L1 retrotransposition suppression while maintaining canonical cytosolic immune-sensing functions 3.
  • Mechanistic grouping of the seven loss-of-function mutations:
    • P486L, L377P, S345L → decreased cGAS–CHK2 binding (upstream phosphorylation arm)
    • D408N, E383K → disrupted phosphorylated-cGAS–TRIM41 interaction
    • E216D, F433L, P486L → attenuated cGAS–ORF2p interaction
  • This separation of function (intact cGAMP synthesis, lost ORF2p restriction) implies the two activities map to distinct structural surfaces and are independently mutable 3.

Mechanistic position — the nuclear-cGAS / TRIM41 regulatory module

Zhen 2023 and Chen 2025 together establish a coherent nuclear-cGAS / TRIM41 / ubiquitin / VCP regulatory module operating on chromatin, in which the substrate of ubiquitination differs but the core architecture is conserved:

PaperSubstrate of TRIM41-mediated ubiquitinationDownstream effectorFunctional outcome
Zhen 2023 (this paper)L1 ORF2pProteasomal degradationL1 retrotransposition suppressed
Chen 2025cGAS itselfVCP/p97-mediated chromatin evictionHR de-repressed; in NMR, TRIM41 activity is weakened → cGAS retained → HR potentiated

The relationship is: Zhen 2023 identifies TRIM41 as the E3 for nuclear cGAS-associated chromatin substrates and establishes the CHK2 → cGAS-phosphorylation → TRIM41 recruitment mechanism; Chen 2025 shows that this same TRIM41 activity turns back on cGAS itself, and that the NMR’s four-amino-acid divergence weakens the TRIM41-cGAS interaction specifically, thereby prolonging chromatin retention and potentiating HR repair. NMR evolution has tuned the TRIM41 regulatory arm to selectively relax cGAS auto-eviction while presumably retaining some ORF2p-targeting capacity.

Aging and senescence relevance

L1 reactivation is a hallmark of aging and cellular senescence. In senescent cells, L1 elements are transcriptionally derepressed (methylation loss, heterochromatin erosion), and ORF2p activity produces cytosolic L1 cDNA, which activates cGAS-STING and amplifies the SASP — connecting L1 reactivation directly to inflammaging 1.

Zhen 2023 establishes that cGAS has a chromatin-protective function antagonistic to L1 transposition, distinct from — and in some ways opposing — its STING-activation role:

  • Cytosolic cGAS function: detects L1 cDNA products → drives STING → inflammaging
  • Nuclear cGAS function (this paper): restricts L1 at the source → fewer retrotransposition events → fewer L1 cDNA copies → less STING activation (indirect)

The direction-of-effect on chronic inflammation therefore depends on which arm dominates in a given cellular context. In senescent cells, elevated CHK2 activity (from chronic DNA damage signaling) may actually potentiate the nuclear ORF2p-restriction arm via the S120/S305 phosphorylation mechanism — a potential compensatory feedback loop. Whether this loop is quantitatively meaningful in aged tissue in vivo remains untested. no-mechanism

Limitations and gaps

  1. Cell-line predominance. Primary mechanistic work was performed in HeLa cells (a cancer cell line) and validated in IMR90-hTERT and HCA2-hTERT (immortalized fibroblasts). Relevance to primary human cells, aged tissue, and in vivo aging is inferred rather than demonstrated. needs-human-replication

  2. Mouse in-vivo data is limited to copy-number increase in young mice. The Cgas knockout mice were 3–4 months old — not aged. Whether L1 copy-number expansion in cGAS-deficient tissue scales with aging and whether it produces functional phenotypic consequences in vivo is not shown. needs-human-replication

  3. Directionality of chronic inflammation not directly tested. The paper does not measure SASP markers, cytokine output, or IFN-stimulated gene expression as a function of the cGAS/TRIM41/ORF2p axis activity. The prediction that nuclear cGAS restriction of ORF2p reduces cytosolic L1 cDNA and thereby dampens STING activation is mechanistically coherent but not directly demonstrated here. no-mechanism

  4. CHK2 as the upstream kinase — specificity. CHK2 is a broadly active DNA damage kinase; other substrates (BRCA2, CDC25A, p53) are also phosphorylated under damage conditions. The contribution of CHK2-mediated cGAS-S120/S305 phosphorylation to L1 restriction specifically (vs. other DNA damage responses simultaneously) is not isolated. no-mechanism

  5. Translation to cancer risk vs aging. The 7 cancer-associated cGAS mutations establish disease relevance for tumorigenesis; whether common aging-associated somatic mutations in CGAS disrupt L1 restriction (vs. just cancer-driver mutations) is not examined. needs-human-replication

Extrapolation to humans

DimensionStatusNotes
Pathway conserved in humans?yesEntire CHK2 → cGAS-pS120/pS305 → TRIM41 → ORF2p-Ub → proteasome axis demonstrated in human cell lines (HeLa, IMR90-hTERT, HCA2-hTERT)
Phenotype conserved in humans?partialHuman cell line evidence for L1 copy-number control; no primary human tissue or in-vivo aging data
Replicated in humans?noNo independent replication in human cohorts or aged primary cells reported

The Cgas knockout mouse data (kidney/brain copy-number increase) provides in-vivo support for the restriction mechanism, but in young mice — not aged. needs-human-replication

See also

  • cgas — protein page; cGAS dual-function biology, nuclear and cytosolic arms; K48-ubiquitination PTM registry
  • trim41 — protein page; E3 ligase architecture; coiled-coil ORF2p interaction surface; Chen 2025 cGAS-eviction role
  • vcp — P97/VCP segregase; acts downstream of TRIM41-mediated ubiquitination of cGAS in the Chen 2025 arm; not directly invoked in Zhen 2023 (ORF2p is proteasomally degraded, not chromatin-evicted)
  • cgas-sting — pathway page; cytosolic-sensing arm driven by L1 cDNA products; nuclear cGAS restriction (this paper) as antagonistic upstream brake
  • genomic-instability — hallmark; L1 retrotransposition as a mechanism of somatic genome diversification in aging
  • cellular-senescence — hallmark; SIPS validation in this paper; L1 reactivation as senescence driver
  • chronic-inflammation — hallmark; L1-driven SASP amplification via cGAS-STING; this paper’s mechanism is an upstream brake on that loop
  • chen-2025-nmr-cgas-hr-repair — mechanistic sequel; same Mao lab; TRIM41 now ubiquitinates cGAS itself; NMR four-AA divergence weakens this → prolonged cGAS chromatin retention → HR potentiated
  • liu-2018-nuclear-cgas-hr-suppression — prior work establishing nuclear cGAS as HR suppressor in human and mouse cells (same protein, different chromatin substrate function)

Footnotes

  1. doi:10.1038/s41586-018-0784-9 · De Cecco M et al. · Nature · 2019 · 1175 citations · closed-access; not in a local paper archive · in-vivo + in-vitro · “L1 drives IFN in senescent cells and promotes age-associated inflammation”; established that L1 reactivation in senescent cells generates cytosolic cDNA that activates cGAS-STING and amplifies SASP; foundational context for L1-aging connection. needs-replication (senescent-cell data primarily murine) ↩ ↩2

  2. doi:10.1038/s41586-018-0629-6 · Liu H et al. · Nature · 2018 · 611 citations · closed-access; not in a local paper archive · in-vitro + in-vivo · “Nuclear cGAS suppresses DNA repair and promotes tumorigenesis”; established nuclear cGAS as an HR inhibitor; prior work contextualizing Zhen 2023 as a third nuclear function (ORF2p restriction) independent of the HR-suppression axis. ↩

  3. zhen-2023-trim41-cgas-l1 · n=null (cell-based mechanistic study; n=6 for retrotransposition assay, n=9 replicates/3 mice per group for in-vivo copy-number) · in-vitro+in-vivo · model: HeLa (etoposide SIPS), IMR90-hTERT + HCA2-hTERT (X-ray 15 Gy SIPS; subcellular fractionation), Cgas-KO mice (3–4 mo; kidney + brain) · Zhen Z et al. · Nature Communications 2023 · doi:10.1038/s41467-023-43001-y · PMID:38086852 · PMC:PMC10716122 · GOLD OA ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21

Graph View

Backlinks